Abstract. Fetal cell transplantation for the treatment of Parkinson's and Huntington's diseases has been developed over the past two decades and is now in early clinical testing phase. Direct assessment of the graft's survival, integration into the host brain and impact on neuronal functions requires advanced in vivo neuroimaging techniques. Owing to its high sensitivity, positron emission tomography is today the most widely used tool to evaluate the viability and function of the transplanted tissue in the brain. Nuclear magnetic resonance techniques are opening new possibilities for imaging neurochemical events in the brain. The ultimate goal will be to use the combination of multiple imaging modalities for complete functional monitoring of the repair processes in the central nervous system. 
Parkinson's disease (PD), first described in 1817 by James Parkinson in a monograph headed "an assay on the Shaking Palsy", is today recognised as the second most common neurodegenerative disorder, with a prevalence of 0.1% of the global population. Interestingly, although PD is an age-related disorder afflicting about 1% of people over 65 years old and 4-5% of people over 85, 5-10% of the patients are under 40, supporting the fact that PD is considered a major social health problem with a significant economic impact [1, 2] . Since PD exists as both an idiopathic and a familial disorder, controversies still persist on the respective contribution of environmental versus genetic factors in the genesis of the disease. Clues regarding the genetic component have derived mainly from identification of mutations or overexpression in genes encoding for various proteins, including parkin, α-synuclein, ubiquitin carboxy hydrolase L1, PINK1 and DJ-1, in familial cases of PD [3, 4] . Environmental factors such as exposure to organic insecticides, herbicides, fungicides or metals have also been identified as potential risk factors in PD [5, 6] . It seems, however, that both familial and sporadic PD lead to a convergent pathogenic pathway involving identical and multifactorial players, identified as mitochondrial dysfunction, oxidative stress and protein aggregation, that are responsible for the damage and loss of dopamine (DA) neurons.
Clinical features
The clinical characteristics of PD include both motor and non-motor manifestations. While the reader is referred to several comprehensive reviews on this topic (see refs. [7] [8] [9] [10] ), here we will give only a brief description of the clinical findings. The cardinal motor features of PD are resting tremor, rigidity, akinesia/bradykinesia and postural instability/gait disturbance, which usually develop over many years as the disease progresses. Tremor, rigidity and akinesia appear as the first components of the syndrome. These symptoms are usually expressed asymmetrically, primarily affecting one segment of the body or a hemibody. Hypomimia and eye blinking, as well as hypophonia, are also early manifestations of the disease. Three to five years after diagnosis, symptoms spread to the contralateral limbs and axial musculature, the disease remaining asymmetrical. Postural instability and gait disturbance occur at a later stage of the disease and lead to loss of equilibrium and falling. PD diagnosis is established when at least two motor symptoms are found, at least one being tremor or bradykinesia, and when patients respond positively to 3,4-dihydroxyphenylalanine (L-DOPA) therapy [11] . Apart from the clinical motor hallmarks, subtle cognitive dysfunctions, abnormalities in autonomic functions and psychiatric disturbances such as anxiety and depression are also reported (see [7, [12] [13] [14] for review).
Neuropathological findings
The phenomenon underlying the occurrence and development of the symptomatology for the vast majority of PD patients remains unknown. In 1895, Brissaud suggested that a neuronal loss at the level of the substantia nigra, a nucleus located in the ventral midbrain that contains high amounts of neuromelanin pigment, might be a key factor for such manifestations [15] . About 10 years later, Lewy described intraneuronal inclusions in the dorsal motor nucleus and the nuclei of Meynert [16] , and Tretiàkoff reported both severe damage in the substantia nigra and the presence of Lewy bodies in the surviving nigral cells [17] . However, it was shortly after the discovery of DA in the brain that patients dying with PD were found to have severe loss of DA in the striatum, a target structure for release of DA produced in the nigral neurons [18, 19] .
The synthesis of DA is regulated by the tyrosine hydroxylase enzyme (Fig. 1a) . Tyrosine hydroxylase catalyses the first and rate-limiting step of the catecholamine biosynthesis by converting tyrosine to L-DOPA, which is then decarboxylated to DA by the aromatic L-amino acid decarboxylase (AADC or DOPA decarboxylase). Once synthesised, DA is taken up into vesicles by the vesicular monoamine transporter. DA mediates its effects by interacting with receptors located on post-synaptic neurons (D 1 and D 2 receptor families), but also binds autoreceptors modulating dopamine cell function presynaptically. While part of the released DA is taken up by the DA transporter (DAT) to the cytoplasm, free DA is metabolised by both monoamine oxidase (MAO) and catechol-O-methyltransferase into homovanillic acid and 3,4-dihydroxyphenylacetic acid (see Fig. 1a for illustration of DA synthesis).
DA-containing systems have been extensively investigated and divided into two major categories based on their anatomical position and connectivity. The mesencephalic DA system consists of the dopaminergic cells located in the substantia nigra (A9 group), DA neurons of the ventral tegmental area (VTA; A10 group) and the retrorubral nucleus (A8 group). Nigral neurons are mainly confined to the pars compacta and pars lateralis of the substantia nigra and give rise to the nigrostriatal and dorsal mesostriatal pathways, whereas the VTA cells and the retrorubral nucleus form the ventral mesostriatal, mesolimbic and mesolimbocortical pathways. The diencephalic DA system includes four topographical subgroups called the caudal diencephalic (A11), tuberal (A12), dorsal hypothalamic (A13) and rostral periventricular (A14) cell groups that project to spinal cord, hypothalamic or pituitary target areas (see ref. [20] for a detailed anatomical description of the DA systems in the central nervous system).
Post-mortem analysis of brains from PD patients revealed that specific subpopulations of dopaminergic neurons are more vulnerable [21, 22] , and that the parkinsonian neurodegeneration is not simply an accelerated form of cell loss that could be seen due to normal aging [23, 24] . Dopaminergic neurons located in the ventral mesencephalon, particularly the cells located in the substantia nigra pars compacta (SNc), are predominantly affected, and their degeneration underlies the dramatic decrease in dopaminergic innervation in the striatum. The first symptoms usually appear when about 50-60% of the neurons in the SNc and about 60-80% of the striatal DA contents are lost [24] [25] [26] . While the degeneration at SNc level is particularly pronounced, other dopamine-containing cell groups such as the VTA and the peri-and retrorubral areas are affected to a lesser extent, and the central grey substance remains nearly intact [27] . The cell loss in the SNc is heterogeneous since it predominantly occurs in the ventrolateral part, explaining the specific pattern of denervation at the striatal level. The neurons that project to the putamen, the dorsolateral and caudal part of the striatum involved in motor functions are more affected than those projecting to the caudate nucleus (ventromedial and rostral striatum) particularly involved in cognitive tasks. Whereas the putaminal DA depletion reaches about 95% in advanced disease, the corresponding decrease measured in the caudate nucleus is around 60-70% [25] . Neurodegenerative changes can also be found at the level of the locus coeruleus, nucleus basalis of Meynert, pedunculopontine nucleus, cerebral cortex and spinal cord, leading to neurochemical alterations in the serotoninergic, noradrenergic and cholinergic neurotransmission systems. These multiple neurotransmission deficiencies, however, seem to occur in the late stages of the disease, whereas other events such as changes in the glutamatergic activity at several levels of the basal ganglia can also be observed earlier in the disease.
Treatment strategies
Pharmacological therapy Considerable efforts have focussed on developing treatment approaches that provide antiparkinsonian benefits. Pharmacological dopamine replacement strategy, by using the DA precursor L-DOPA, has been the major treatment since its introduction in 1967 [28] . However, even if the symptomatic benefits of this medication are remarkable in the early stages of the disease, the majority of PD patients develop motor complications during long-term therapy. Indeed, with disease progression, these complications consist of marked swings between immobility and mobility (on-off motor fluctuations) and involuntary movements (dyskinesia) but neuropsychiatric complications and non-motor fluctuations can also occur [7] . It has been speculated that the main factors responsible for such side-effects are directly related to the increasing dopaminergic nerve terminal loss and a pulsatile stimulation of DA receptors due to the short plasma half-life of L-DOPA [29] [30] [31] . Because of their longer plasma half-life, dopaminergic agonists have been proposed as a strategy to induce symptomatic benefits without adding severe motor complications. Existing compounds used as either mono-or multitherapy (i.e. associated with Fig. 1 . Schematic drawing of a synaptic terminal of a nigrostriatal dopamine (DA) neuron and its post-synaptic target, striatal GABAergic projection neuron. Normal DA neurotransmission is displayed in a. Dietary tyrosine enters the brain via active amino acid transport. In the DA neuron, tyrosine is converted to DA in two steps: The first and rate-limiting step is the synthesis of L-3,4-dihydroxyphenylalanine (DOPA) by the enzyme tyrosine hydroxylase (TH). The second step is catalysed by aromatic amino acid decarboxylase (AADC). Newly synthesised cytoplasmic DA is then captured in specialised vesicles by the vesicular monoamine transporter-2, and released into the synaptic cleft upon activation. On the post-synaptic side, DA binds to its specific receptors (D 1 and D 2 receptor families) to mediate its actions. DA is then either metabolised extraneuronally into homovanillic acid (HVA) by monoamine oxidase (MAO), or taken up by the presynaptic terminals by the DAT to be re-vesicularised or metabolised into 3,4-dihydoxyphenylacetic acid (DOPAC) by catechol-O-methyl-transferase (COMT). In b-d, three different PET ligands used for visualisation of the DA system are illustrated. First, radioactive fluorine substituted L-DOPA ( 18 F-DOPA) can be administered systemically. Upon entrance into the DA neuron, the labelled precursor is converted to 18 F-DA and stored in vesicles, thus giving an estimation of total storage capacity (b). Another way to label the presynaptic neurons is to use a specific ligand ( low doses of L-DOPA) already contribute efficiently in counteracting motor symptomatology of PD patients [31] [32] [33] .
Because of evidence that non-dopaminergic alterations are associated with the characteristic nigrostriatal neurodegeneration in PD patients, other options have been evaluated as alternative treatment strategies. As an example, pharmacological approaches targeting glutamate receptors, particularly the N-methyl-D-aspartate (NMDA) receptors, have been investigated and have shown beneficial effects in reversing the motor symptoms and also the L-DOPAinduced dyskinesia in patients with motor complications [34, 35] . Use of these agents has, however, been limited because of the adverse effects associated with non-selective blockade of NMDA receptor function. Development of more potent and selective pharmaceuticals for both ionotropic and metabotropic glutamate receptors holds promise for future therapeutic approaches.
Cell therapy Fetal ventral mesencephalic tissue transplantation based on the rationale of restoring dopaminergic neurotransmission in the striatum has been investigated as a novel strategy for PD [36] . Clinical data, based on observations in about 350 grafted-patients, demonstrated that embryonic human nigral neurons were able to survive, integrate and function over a long time in the brains of parkinsonian patients [37] . However, although grafts can induce symptomatic relief, the clinical outcome is variable. Current efforts are focussed on optimisation of cell therapy to attain the best possible outcome and to achieve it consistently. In particular, issues currently under debate are: increasing graft efficiency and decreasing functional variability, selection of patients most suited to receive striatal dopamine cell transplants, placement of the fetal mesencephalic tissue to achieve the best striatal re-innervation and best clinical outcome with no side-effects, and standardisation of the procedures for preparation of the graft tissue [37, 38] .
Available clinical and experimental data indeed point to the fact that transplant-induced recovery is significantly better in younger than in older subjects, suggesting that age and disease severity must be considered important factors in the functional efficacy of the graft [39] [40] [41] [42] . Moreover, since outgrowing axons seem to extend 2-3 mm from the transplantation site, graft placement also appears to be a critical parameter. DA depletion is known to be widespread, involving various structures, from the putamen to other parts of basal ganglia, limbic forebrain and cerebral cortex. Since this neuronal loss differs from one patient to another, placement of the dopaminergic transplants has to be personalised (for review, see ref. [37] ). The composition and preparation of the graft tissue also appear critical for optimisation of graft-induced functional recovery. Indeed, procedures for dissection of the fetal brain material and preparation of the tissue for transplantation have an impact on the outcome of the grafting. For example, injection of cell suspension is more favourable than use of solid tissue grafts since suspension grafts appear to induce less immunogenic responses, possibly because the blood capillaries within the graft belong to the host rather than the donor tissue, as would be the case in solid grafts. Finally, appropriate long-term immunosuppressive treatment appears to be necessary to ensure the full functional potential of the transplants.
Huntington's disease
Huntington's disease (HD) is an inherited, autosomal dominant, neurodegenerative disorder characterised by involuntary choreiform movements, cognitive decline and a progressive neuronal degeneration primarily affecting the striatum. At present there is no effective therapy, even palliative, against this disorder. The gene responsible for the disease has been localised on the short arm of chromosome 4 [43] and the molecular defect recently identified [44] as an abnormal repeat of CAG triplets in the 5′ coding region of a gene (IT15) encoding a protein (huntingtin) with unknown function. Despite the intense search for a cell pathology attached to this molecular defect, the mechanisms leading to neurodegeneration in HD remain largely speculative. Nevertheless, recent studies have suggested that abnormal interactions between the mutated huntingtin and other proteins could be involved in the pathogenesis of HD. Thus, huntingtin has been shown to interact with several proteins, including a cytoplasmic protein that associates with microtubules, mitochondria and synaptic vesicles (HAP-1 [45] ), glyceraldehyde phosphate dehydrogenase (GAPDH [46] ), an unidentified calmodulinassociated protein [47] , a ubiquitin-associated protein (HIP-2 [48] ) and a protein homologous to the yeast cytoskeleton-associated protein sla2p (HIP-1 [49] ). These observations suggest that alterations in glycolysis, vesicle trafficking or apoptosis could all be pathological mechanisms involved in HD. However, direct and indirect evidence for defects in mitochondrial energy metabolism (complex II-III deficiency) has been increasingly compelling over the past decade [50, 51] . It is conceivable that a complex interplay, and possibly a direct link, exists between HD mutation, mitochondrial impairment, excitotoxicity/apoptosis and striatal neurodegeneration.
Clinical features
It is beyond the scope of this chapter to give a full description of HD, and the reader is referred to review articles on the topic for more detailed information [52, 53] . However, a brief summary of the most relevant neuropathological and clinical features of HD will be given below. HD is characterised by abnormal choreiform movements, cognitive deficits and psychiatric manifestations associated with progressive striatal atrophy. The onset, progression and clinical expression of HD are variable even though it occurs in general during adulthood. In the common form of the disease, clinical symptoms develop very rapidly after onset and compose a three-part picture with motor symptoms, initially characterised by hyperkinesia evolving to bradykinesia; psychiatric disturbances, with aggressiveness and depression; and profound cognitive impairment. With the exception of patients bearing the largest triplet repeats (juvenile variant), in whom the disease normally becomes clinically overt within a few years after birth, most HD patients start to express motor abnormalities at ages 30-40. In the most common form of the disease, motor disabilities progress over a 10-to 15-year period from a hyperkinetic to an akineto-rigid syndrome. Typically, the earliest motor signs are eye movement abnormalities, followed by the progressive appearance of orofacial dyskinesias, dyskinesias involving the head, neck, trunk and arms, and finally chorea [54] . As the disease progresses, choreiform movements may disappear, the initial hyperkinetic syndrome being progressively replaced by a more hypokinetic syndrome in which bradykinesia, rigidity and dystonia may predominate [55] . In the juvenile variant, choreiform movements are generally absent, whereas dystonia and bradykinesia can been seen in the early stages of the disease, evolving rapidly to rigidity and severe hypokinesia.
Comparative neuropsychological testing of patients with HD, PD with dementia or Alzheimer's disease (AD) points to HD as a model of subcortical dementia, even if this concept has been a matter of controversy (see ref. [56] for discussion). Nevertheless, the cognitive deficits observed in HD are very similar to those observed following lesions of the frontal cortex, and perseverative behaviour and severe impairment in set-shifting strategies ("cognitive flexibility") are key features of the frontal-type HD syndrome.
Neuropathological findings
The most striking neuropathological manifestation of HD is the progressive degeneration of the striatum (caudateputamen complex). The degree of striatal atrophy has been used by Vonsattel and collaborators [57] to categorise HD brains into five different grades (from grade 0, no striatal pathology, to grade 4, severe caudate-putamen and nucleus accumbens atrophy). At this latest stage of neurodegeneration, atrophy is also readily observed in the cerebral cortex (frontal and prefrontal areas), pallidum, subthalamic nucleus, various thalamic nuclei and substantia nigra. Interestingly, all these areas have in common the fact that they belong to the basal ganglia circuitry and, as such, are directly or indirectly connected to the striatum. However, only the severity striatal atrophy has been shown to correlate with the severity of psychiatric and motor symptoms [58] .
An interesting feature of HD striatal pathology is that not all striatal cells are equally affected by the degenerative process [59] . There is a preferential degeneration of γ-aminobutyric acid synthesising (GABA-ergic) mediumsized spiny neurons and a relative sparing of the other subpopulations of striatal cells, at least in the early course of the disease [60] . Consequently, concentrations of substance P and Met-enkephalin that co-localise with different subsets of GABA neurons in the striatum, as well as the post-synaptic D 1 and D 2 dopaminergic receptors, are decreased [61] [62] [63] . Decreased numbers of neurons immunoreactive for calbindin D28k, a Ca 2+ -binding protein present in a subset of striatal medium-sized spiny neurons, has also been reported. Interestingly, Golgi staining studies demonstrated that before death, many striatal GABAergic neurons show morphological abnormalities in moderate grades of HD [64] . Changes in immunoreactivity for calbindin or Golgi staining indicate the presence of proliferative dendritic changes early in the disease. These morphological changes include increased size and density of dendritic spines, recurving of distal dendritic segments and shortsegment branching along dendrites. Even within the subpopulation of GABAergic spiny neurons, all cells are not similarly affected by HD. A double gradient of striatal degeneration has been described in the HD striatum, one progressing in a dorsoventral direction and another in a caudorostral direction [57, 65] . As a consequence, the most vulnerable GABAergic neurons appear to be located mostly within the dorsal parts of both caudate and putamen nuclei. Another intriguing neuropathological characteristic of HD is the relative sparing of the medium-sized interneurons positive for NADPH diaphorase and somatostatin [60] . The preservation of this subset of striatal interneurons is associated with an increase in somatostatin and neuropeptide Y concentrations [66] . The enzyme responsible for the labelling of the medium-sized aspiny neurons within the striatum using NADPH diaphorase activity turned out to be nitric oxide synthase (NOS) [67, 68] . This striking sparing of NOS-positive interneurons and the possible neurotoxicity of NO led to the hypothesis that these interneurons may have a causal role in the pathogenesis of HD [69, 70] . The large cholinergic interneurons are also spared in HD striatum, even though choline acetyltransferase activity and muscarinic receptors are significantly decreased, probably as a result of synapse loss due to the loss of neighbouring neurons [71] . Concentrations of dopamine and its metabolites are not markedly decreased and tyrosine hydroxylase immunoreactivity is maintained in the HD striatum [72, 73] . Finally, it can be noted that all major striatal afferents (in particular the dopaminergic, glutamatergic and serotoninergic afferents) are relatively unaffected by the degenerative process [67, 74] . Another characteristic of HD neuropathology is the presence of intranuclear inclusion bodies and extracellular fibrillar deposition that consists of the ubiquitinated N-terminal part of huntingtin, the mutated protein in HD [75] .
Hypothesis on cell death mechanisms
The exact link between the proteins potentially interacting with huntingtin and the pathological process occurring in HD remains to be clarified. However, one hypothesis is a potential toxicity of the N-terminal part of the mutated human huntingtin. The mechanisms underlying cell death in HD remain largely unknown, though a number of triggering events leading to neuronal death have been iden-tified to date, such as excitotoxicity (a term designating death resulting from excessive activation of glutamate receptors). The possibility that excitotoxicity may play a role in the aetiology of HD was supported mainly by the finding that focal injection of glutamate receptor agonists into the striatum produced lesions with histological and neurochemical characteristics resembling those seen in HD [75] . This hypothesis was later refined by suggesting that early energy impairment observed in HD patients may lead to the overactivation of NMDA receptors and relentless excitotoxic neuronal death [76] . Experiments on neuronal cell cultures and laboratory animals in vivo have suggested that mild energy failure could indirectly produce activation of an NMDA receptor, triggering an excitotoxic cascade and, subsequently, actual neurodegeneration. Defects in energy metabolism in HD patients have been demonstrated in vivo using positron emission tomography and nuclear magnetic resonance spectroscopy. Biochemical analyses of post-mortem tissue samples from HD patients have consistently shown a decrease in activity of complex II-III (succinate dehydrogenase and ubiquinone cytochrome c oxidoreductase). The possibility that the defect in complex II-III activity seen in HD may have a causal role in the aetiology of the disease is also suggested by the fact that well-characterised cases with biochemical defects in succinate dehydrogenase are associated with preferential striatal degeneration [77, 78] . In addition, poisoning with the succinate dehydrogenase irreversible inhibitor 3-nitropropionic acid in humans results in striatal lesions [79] .
Finding new therapies for HD
Although neuroleptics are used worldwide to reduce the frequency and intensity of the motor symptoms, today there are no specific drug-based treatments available for HD patients. Despite the lack of an exact understanding of the cell death mechanisms in HD, major efforts are currently being undertaken to find a cure. Two basic features of the disease allow two lines of therapeutic strategy to be designed: first, the predominant degeneration in the striatum, and second, the neuronal loss progression over years after the onset of clinical signs. It may thus be possible to consider substituting missing striatal neurons in patients by homologous neurons that can replace them functionally and anatomically. This line of clinical research therapeutics is currently based upon the use of intracerebral grafting of fetal neural tissue. The safety of the procedure has now been demonstrated [80, 81] . In addition, some therapeutic efficacy has been shown following fetal neural allografting, with long-term stability of performances and clinical improvements in some symptoms [81] . A multi-centre study involving a sufficiently large number of patients to permit a valid group analysis, and therefore the comparison of a treated group with a matched control one, is currently being actively pursued.
In parallel, one can also consider treatments that would strengthen the natural defence of neurons and, therefore, allow threatened neurons to survive, at least for a longer period. This is the focus of studies based upon the use of neuroprotective drugs or trophic factors. Simultaneously, ex vivo gene transfer techniques using encapsulated genetically engineered cells have been used to test the neuroprotective properties of ciliary neurotrophic factor (CNTF) in HD patients. In this context, intraventricular implantation of CNTF-producing capsules in HD patients for 1 year proved to be a safe procedure, with no noticeable adverse events [82] . This encouraging phase I trial will be followed soon by a phase II protocol. Other gene-based strategies include inactivation of the mutated gene expression using viral vector-mediated delivery of silencing RNA directed against the mutated HD gene. This therapeutic strategy, which is currently being tested in animal models, is facing the technical problem of how to disperse a sufficient amount of the viral particles over large brain regions such as cortical and/or striatal territories.
General concepts in positron emission tomography
Positron emission tomography (PET) is a complex and costly technology. In principle, PET imaging is based on the use of radiolabelled ligands (molecules that can be receptor ligands, enzyme substrates, false neurotransmitters etc.) which can label specific molecular targets in living organisms following an intravenous injection. This approach is multidisciplinary in essence as it requires radiochemists to synthesise the positron-emitting molecules, pharmacologists and biologists to validate them as specific radiotracers in vitro and in vivo, and various other expertises to be able to qualify these radioligands as radiopharmaceuticals, adapted for a clinical use. Nevertheless, PET imaging is unique in that it offers the opportunity not only to visualise but also to quantify activity of cells in specific organs or tissues under examination, providing direct information on the chemistry and function of that area.
The principles of PET
Upon decaying, certain radionuclides emit positrons that travel only about a millimetre in tissue before being captured by an electron. Both particles spontaneously annihilate in a matter-anti-matter reaction, which produces two 511-keV gamma-ray photons travelling in exactly the opposite directions (180°apart from each other). A ring of hundreds of scintillation crystal detectors surrounding the object to be imaged is wired to detect such coincident pairs of gamma rays, which, in turn, allows the location of the annihilation event to be traced along the line connecting the two detector points. A computer uses this information to generate three-dimensional, cross-sectional (tomographic) images that represent the biological activity where the radiolabelled compound has accumulated. Modern clinical PET scanners are equipped with 25-32 detector rings, which can simultaneously acquire multiple adjacent images (up to 63), providing a three-dimensional view of the body or whole organs such as the brain with an in-plane resolution of 4.5 mm. After a complete scan, a mathematical algorithm applied by the computer corrects the collected data for scatter, attenuation and accidental coincidences, normalises for the differences in detector efficiencies and reconstructs the spatial distribution of the radioactivity density inside the organ or the system under study. The resulting image can be displayed on a screen, stored and/or further analysed and processed.
After injection of a trace amount of a radiotracer, PET can map the distribution pattern of the radioactivity with a million-fold better sensitivity than other techniques. Its spatial resolution is adequate for most purposes and relates to the size and number of detector crystals used in the PET tomography. Typically, a PET volume element (voxel) has dimensions of one to a few millimetres. PET has recently been miniaturised, making it applicable to small animal imaging, but the technique is above all a nuclear medicine imaging technique that is nowadays widely used in oncology as a highly sensitive means of detecting tiny tumours in the living body, including the brain.
PET studies range from standard image displays that provide direct indices of physiological function to more complex kinetic analysis methods using compartmental modelling approaches which provide quantitative assessment of binding parameters (B max and K d ) or V max values. Depending on their biochemical properties, PET radiotracers may be divided into two categories. The first category includes non-specific radiotracers following a biochemical pathway and allowing for measurement of tissue extraction or metabolism. Radiotracers from the first category include 18 F-fluorodeoxyglucose ( 18 F-FDG), used as a tracer to map glucose metabolism in the brain and, using an appropriate compartmental modelling approach [83] , to perform absolute quantification of regional glucose metabolism in vivo. A second example is 15 O-labelled water (H 2 15 O), which is used as a tool for the estimation of physiological parameters such as oxygen metabolic rate and cerebral blood flow. In addition, the short half-life of 15 O (t 1/2 =2.1 min) allows for rapid sequential measurements (PET activation studies) of cerebral blood flow using H 2 15 O. Radiopharmaceuticals from this category may be assessed using a single-or two-compartmental plasma-tissue model. The second category includes specific radioligands involved in an interaction with a transporter or a receptor site. Radiotracers from the second category are used to study changes in the density and affinity of central receptors, and are described in detail in the following section.
Applications of PET in neurodegenerative states
PET was the first scanning method to provide information on brain function. Several neurological and psychiatric diseases have been related to neurotransmitter and receptor disorders. Owing to its high sensitivity, today PET is used to detect and quantify subtle abnormalities in neurotransmission or neurotransmitter levels in neurological disorders, including stroke, epilepsy, AD, PD and HD. There is now a validated radiotracer adapted to the study of almost all major neurotransmitter systems (for a review see [84] [85] [86] , such as the dopaminergic, noradrenergic, serotoninergic, cholinergic and GABAergic (GABA-A benzodiazepine receptor complex) neurotransmitter systems, as well as, more recently, the glutamatergic [87] neurotransmitter system. The information provided by PET may vary from one pathology to another because of variation in the primary degenerative defect involved in the pathology. For example, PET studies in PD have been focussing on molecular imaging of the dopaminergic system (the DA metabolism, the DA receptor occupancy or the DA transporter density) whereas studies in AD have focussed on the general rate of metabolism in parts of the forebrain, inflammation and/or tracers for the amyloid plaques as surrogate markers of the pathology.
The role of PET imaging in neurodegenerative diseases has been multiple and complementary to that of other imaging modalities. One of the first applications of PET was to help characterise the role of a given neurotransmitter system in important functions such as motor control and the presence of subtle dysfunctions in living patients (see ref. [88] for review). For example in PD, PET imaging has been used in at least four different approaches. The loss of dopamine terminal function, as reflected by decreased levels of striatal and extrastriatal 18 F-fluoroDOPA uptake ( Fig. 1c) , has been correlated with motor disability as well as cognitive performance [88] . Second, alterations in motor behaviour in response to focal intrastriatal dopamine replacement by implants of fetal mesencephalic cells or local trophic factor infusions have been correlated with restoration of dopaminergic function in treated patients [89, 90] . Third, alterations in the patterns of resting and activated blood flow and metabolism in PD patients following dopamine replacement therapies have been characterised by PET [91] . Finally, dopamine release in striatal and also extrastriatal (mostly cortical) areas during task performance or pharmacological challenge has been shown using the indirect 11 C-raclopride PET approach [92, 93] , an in vivo PET technique based on the competition between the 11 C-radiotracer and the endogenous levels of dopamine either released by task or pharmacological challenges (amphetamine, methylphenidate, L-DOPA) or even under basal conditions [94] (Figs. 1d, 2) .
Another important application of PET in neurodegenerative disease has been to help establish better diagnosis of uncommon forms of neurodegenerative disorders. For example, PET has been used in combination with dopaminergic pre-and post-synaptic markers like 18 F-DOPA and 11 C-raclopride to differentiate between typical PD, in which no major loss in post-synaptic D 2 receptors occurs, and other parkinsonian syndromes, such as striatonigral degeneration or Steele-Richardson syndrome, in which a significant loss of post-synaptic dopamine receptors can be demonstrated in the striatum. However, even if PET imaging actually provides functional information to confirm the clinical diagnosis, it is worth noting that the use of PET on its own is not sufficient to diagnose a disease, as many syndromes may also be associated with similar alterations of the binding properties of a given radiotracer. In addition, using radiotracers other than the classical 18 F-DOPA, PET can identify alterations in other catecholaminergic neurotransmitter systems and demonstrate that depression and anxiety in the patients are correlated with specific loss of DA and noradrenergic innervation in the limbic system [95] .
The third very important application of PET in neurodegenerative diseases such as PD or HD has been in the in vivo monitoring of disease progression. In this respect, PET imaging is nowadays frequently employed in clinical research to help quantify the annual rate of loss of specific markers such as DA synthesis in PD or D 2 receptor expression in HD patients. Similarly, in HD patients, the initial PET studies carried out by Kuhl and collaborators [96] showed that cerebral glucose metabolism was affected in the striatum of HD patients. Marked decreases in glucose consumption in symptomatic HD patients could be attributable at least in part to striatal atrophy. However, substantial reductions in 18 F-FDG incorporation in the striata of patients presenting early symptoms with no gross atrophy were seen, suggesting that severe metabolic impairment could precede bulk tissue loss. Of 15 at-risk patients, six showed striatal glucose utilisation that was more than 2 standard deviations lower than the normal mean value [96] . These initial observations were confirmed by a number of other studies where alterations in striatal glucose metabolism were seen in early or presymptomatic HD patients [97, 98] . However, a decrease in striatal glucose consumption in at-risk patients was not always observed [99] . Moreover, it is worth noting that such studies may be confounded by the fact that, for reasons mainly associated with ethical considerations, the patients may have to take medications that most of the time compete competitively with the radiotracer used (for a review, see [100] ).
The last point, and probably the most awaited, is the use of PET for the in vivo assessment of therapeutic efficacy. Major recent interest in the role of PET has arisen following the completion of several large clinical trials evaluating the effect of chronic pharmacological treatment on disease progression. For example, in the REAL-PET study, patients treated with the DA agonist ropinirole had a significantly lower reduction of striatal and nigral 18 F-DOPA uptake over 2 years compared with patients in the L-DOPA-treated control group [101] . Similarly, restoration of striatal DA storage and release has been achieved by transplantation of fetal ventral mesencephalic tissue into the diseased brain. Evidence for graft survival and striatal re-innervation has been assessed post-mortem in patients who received transplants of fetal dopamine cells in the striatum [41, 42, 102, 103] . Graft viability has also been shown using PET [36, 41, 42, [104] [105] [106] . Importantly, the recovery of dopamine function 3 Fig. 2 .
11 C-raclopride PET is a useful tool to assess DA neurotransmission in healthy and parkinsonian brain. While normally both DA and raclopride partially occupy the D 2 receptor sites located on the striatal neurons and give a specific signal proportional to 11 C-raclopride bound to the receptors (a), in the parkinsonian brain (where DA neurons are lost) was found to be dependent on the amount of fetal tissue implanted [107] . Recently, the graft's functionality has been investigated by Piccini and colleagues, where DA release from the fetal DA neurons was visualised using 11 Clabelled raclopride [89] . This was followed by a second study where the recovery in motor performance in grafted patients was correlated with reactivation of the frontal cortical areas using H 2 15 O PET, suggesting that functional recovery requires integration of the graft into host circuitry [108] .
Similarly, using 18 F-FDG as a marker of hexokinase activity, PET has been used to study the metabolic effects of intrastriatal grafting in HD patients implanted with embryonic striatal neuroblasts [109] . As mentioned earlier, the PET signature of HD is largely characterised by a severe hypometabolism in the striatum and several, mostly cortical, extrastriatal regions. Whereas the striatal hypometabolism can certainly result from the severe cell losses occurring in these structures, the cortical hypometabolism may also result from a functional impairment of striatocortical pathways resulting from the progressive disappearance of striatal neurons in the striato-pallido-cortical loops. The PET study in grafted patients shed new light on these issues by providing three major observations. First, it showed a parallel improvement in clinical status and striatal metabolism in three grafted patients (out of the five who were involved in this small clinical trial), demonstrating that fetal grafts in the striatum of HD patients are able to restore some striatal function in otherwise metabolically impaired patients. Secondly, the same PET data showed that the extent of the cortical hypometabolism observed before grafting was either reduced or stabilised in the same three patients showing clinical improvement. Conversely, in the two patients who did not show clinical improvement, striatal and cortical hypometabolism worsened. These results indicate that the clinical benefit provided by the grafts in the first three patients was related to the functional improvement in the impaired striatocortical loops. Of major interest in the context of HD, the reversibility of the cortical hypometabolism after striatal grafting (at least at an early stage of the disease) means that it is not related only to the degeneration of cortical neurons, providing support to the rationale for intrastriatal grafting in HD.
The third major finding in the aforementioned study was that striatal grafts displayed heterogeneous anatomical and metabolic profiles both within and across patients, which may provide a means to better understand the relationship between metabolic profile and functional recovery after cell therapy. The explanation for this heterogeneity in graft development and metabolism remains speculative. It might be related to the number of surviving cells and to the proportion of striatal tissue included in each implant or to the degree of reconnection of striatal grafted tissue with the host systems. It remains the fact that the FDG uptake is mainly related to synaptic activity and that clinical improvement was observed only in those patients whose grafts induced an increase in global striatal and cortical metabolism.
General concepts in magnetic resonance techniques
The nuclear magnetic resonance (NMR) technique is built on the principle that every magnetic nucleus (including those in biological organisms), placed in an outer magnetic field, may be excited by applying a short pulse of energy. The specific frequency for each nucleus (called the Larmor frequency) depends on the gyromagnetic ratio of the nucleus, the field strength and interactions with surrounding nuclei. The resulting signal can be visualised in two different ways (Fig. 3) . When the frequency spectrum of the signal from the whole or part of an object is presented, the technique is called magnetic resonance spectroscopy (MRS) (Fig. 3c,d) , while mapping the intensity of the signal in space is referred to as magnetic resonance imaging (MRI) (Fig. 3a,b,g,h) . The relaxation of a paramagnetic nucleus can be investigated looking at two components of the relaxation, the spin-lattice relaxation (T1) or the spinspin relaxation (T2). Using different time intervals between excitation pulse and detection (termed echo time; TE) and/ or between repetitions (TR), the signal will have a different contribution ratio between T1 and T2 relaxations. We therefore refer to the resulting image as "T1-weighted" when the signal is formed mainly by the contribution from T1 relaxation (Fig. 3a) and as "T2-weighted" when T2 relaxation is the dominant factor. Note that in reality all images have some contribution from both sources, and one can never separate them totally.
Due to the fact that water constitutes 50-70% of all soft tissue mass in the body, the MR signal from the hydrogen atom ( 1 H) gives by far the highest signal of all nuclei. Based on the cell composition in different parts of the brain, the water protons have a different microenvironment and therefore behave slightly differently. For example, in voxels containing myelinated axons (i.e. white matter tracts), there is a higher concentration of lipids compared with voxels containing cell bodies and non-myelinated axons, as is the case in grey matter. Using specific TE and TR values we can construct an image of the brain with high contrast between the white and the grey matter. The more heterogeneous the tissue composition, the better is the potential for high contrast. As a result, MRI has the strength of providing high-resolution (sub-millimetre scale) morphological images of the brain matter [110] . MRS, on the other hand, can give information on the chemical composition of areas in the brain. Each peak in the MR spectra corresponds to a specific resonance frequency (chemical shift) and represents a distinct position of a paramagnetic nucleus, providing an NMR fingerprint of each molecule (Fig. 3c,d) 1 H MRS in the brain are N-acetylaspartate (NAA), lactate, glutamine/ glutamate, creatine (Cr), phosphocreatine (PCr), choline and myo-inositol [111] . The concentration and the uniqueness and width of the MRS peaks produced by the compounds are the major factors that determine the smallest detectable amount of a substance in the brain. As a guideline, around 0.5-1 mmol is the lowest amount detectable in the clinic during a regular 1 H-MRS examination of the brain. Detection of minor metabolites present at low concentrations in the brain is hampered by limited sensitivity, spectral overlap with signals from major metabolic components and structural background from macromolecules.
Functional MRI (fMRI) is another NMR-based imaging modality, which uses the blood oxygen level dependent (BOLD) parameters to infer brain activity. The BOLD principle is based on the fact that deoxyhaemoglobin is paramagnetic (i.e. is attracted to a magnetic field) whereas oxyhaemoglobin is only weakly diamagnetic. An increase in the concentration of deoxyhaemoglobin in a voxel will lead to inhomogeneities in the magnetic field and thereby result in a decrease in the T2* [112] . When an area of the brain is activated, there is an increase in oxygen consumption that results in a slight initial increase in deoxyhaemoglobin, but this increase is very soon replaced by a larger decrease due to an oversupply of oxygenated blood. Thus, by using a series of echo-planar image stacks acquired in interleaving on and off states of the stimulation of interest, regional elevation in signal intensity can be correlated to activation in defined regions of the brain, for the most part in the cortical areas [112] .
Diffusion-weighted imaging (DWI) and diffusion tensor imaging (DTI) are comparatively new techniques within the field of MR and are based on the Brownian motion of water molecules in the tissue. While the water molecules display homogeneous (isotropic) diffusion properties in a pure liquid environment, in the heterogeneous brain tissue, movement is not free in all directions but follows a pattern based on the tissue structure (anisotropic diffusion). It is believed that the water molecules diffuse more easily along the fibre bundles in the white matter than perpendicular to them [113, 114] . Using DWI acquisition techniques, the mean travelling distance in each axis can be acquired in diffusion maps from which one can calculate the apparent diffusion coefficient (ADC) for each voxel. DTI, on the other hand, uses quantitative acquisition of the diffusion in 3 Fig. 3 . Multi-modality non-traumatic imaging approaches suitable for the in vivo assessment of cell-based therapies. a T1-weighted MRI displaying the brain anatomy of a patient suffering from HD. Note the enlargement of the lateral cerebral ventricles and the bilateral atrophy of the caudate-putamen complex. b 18 F-FDG PET image of the same patient's brain, displaying the regional cerebral metabolic rate of glucose. The PET image (coded in false colours, with red displaying high metabolic rates and yellow, green and blue respectively displaying intermediate, low and very low metabolic rates) is superimposed on the MR image taken at the very same brain level. In this transplanted patient, the striatal graft (intercept of the two white lines) is characterised by a high metabolic rate of glucose, indicating viability of the transplanted neurons. c, d Nuclear magnetic spectroscopy spectrum acquired in vivo in the striatum of a primate. Depending on the strength of the magnetic field used, the technique makes it feasible to quantify up to ten cerebral metabolites such as phosphocreatine (a high-energy compound), glutamate (the excitatory neurotransmitter), glutamine (a glial marker), GABA (the inhibitory neurotransmitter) or Nacetylaspartate (a marker of neuronal integrity). e, f Diffusionweighted imaging (e) and fibre tracking (f) in a human volunteer. In e, the fractional anisotropy in each voxel of the image is colourcoded to display in three dimensions the main organisation of the fibre bundles in the living human brain. In f, the main fibre bundles are extracted and represented in three dimensions. g Multifocal glioblastoma multiforme: T1-weighted coronal image after i.v. contrast injection. h 3D inflow MR angiography (MIP) without contrast injection. g and h are courtesy of Dr. Elna-Marie Larsson at Lund University Hospital and were acquired using the 3T Philips Intera MR scanner six or more directions in order to calculate a tensor that describes the shape of a diffusion ellipsoid in that voxel. The more elongated and cigar shaped the ellipsoid, the more anisotropic is the diffusion. This information can then be displayed in a 3D vector field that can be used as a basis for tractography [reconstruction of tract trajectories (Fig. 3e)] , thereby visualising the extent of major fibre tracts in the brain [114] . Using this technique, distortions in major fibre tracts can be investigated (Fig. 3f) .
Contrast agents and labelling compounds have turned out to be one of the most difficult aspects of MRI, but a few alternatives exist, with gadolinium (Gd) chelates being the most used contrast agents to date. Gd contrast agents work by interaction between the Gd chelate and the surrounding water molecules. This interaction accelerates the T1 relaxation of the water molecules and thereby increases the signal at certain pulse sequences. Gd contrast agents are successfully used in applications such as visualisation of brain tumours (Fig. 3g) , localisation of blood-brain barrier disruption (e.g. in stroke) and angiography (Fig. 3h) . In fact, about one-third of all MRI examinations performed in the clinic today make use of contrast agents, with Gd chelates being used in the great majority [115] . All clinically approved Gd complexes are intravenously administered, non-specific agents without any cellular or molecular recognition capabilities. To further advance the possibilities of MRI in cell therapy and other MR applications, novel specific contrast agents must be developed.
MR in neurodegenerative states
Like other neurodegenerative diseases, PD is associated with subtle structural changes that are difficult to detect by traditional MRI techniques. Volumetric MRI indicates only modest regional morphological changes in extranigral brain structures of patients with advanced PD, whereas reliable MRI markers of underlying neurodegenerative abnormalities are yet to be developed [116] . Based on the anatomical MR images and optimised voxel-based morphometry, it has been shown that changes occur in many areas of grey matter, e.g. in the hippocampus, anterior cingulate gyrus and superior temporal gyrus [117, 118] . Volumetric MRI analysis could also prove to be important for differential diagnosis between typical idiopathic PD and the striatonigral variant of multiple system atrophy (MSA-P). This differentiation is otherwise difficult due to similar signs and symptoms, especially at disease onset. There appears to be a larger decrease in the putaminal volume in MSA-P than in PD, compared with controls [119] . Similar to this, other groups have found that differences in the trace of diffusion tensor values or magnetisation transfer of the putamen and globus pallidus also successfully differentiate between MSA-P and PD [120, 121] . Similar studies have been conducted on HD patients to show a global decrease in brain volume as well as a localised decrease in volume coupled with an increase in mean ADCs in the caudate nucleus compared with healthy control subjects [122] . Moreover, MRI examinations in patients with early-onset HD showed abnormalities in signal intensity indicating necrosis and a rapid process of degeneration [123, 124] .
Many studies have been conducted using MRS on PD and HD patients with the hope of finding patterns of metabolites that could aid in early diagnosis and understanding of the disease. However, clinical 1 H-MRS studies (at 1.5 T field strength) have failed to detect regional metabolite changes in multiple brain structures and tissues in patients with PD, other than some loss of creatine in the region of the substantia nigra, which could possibly be caused by pharmacological treatment [116] . The major disadvantage of this approach is that none of the more specific neurotransmitters and metabolites of interest can be detected owing to the low available concentrations and the low sensitivity of the technique. Therefore all studies have looked at only major metabolites such as NAA, Cr and PCr (Cr and PCr cannot be separated in 1 H-MRS) or lactate. In HD patients, evidence for alteration in energy metabolism comes from the study of cerebral concentrations in lactate using MRS, in which substantial increases were seen in the striata but also in the occipital cortex, a brain region with no ongoing process of neurodegeneration, [125, 126] . This observation points to an alteration of oxidative metabolism in HD, in line with the results of several biochemical studies demonstrating alteration of the mitochondrial complex II activity in HD [50, 127] . NAA has also been used as a marker for viable neurons but it is very unspecific and has also been shown to exist in high amounts in, for example, astrocyte progenitor cells [111] . Creatine has been used as an indicator of defective energy metabolism but has an even less defined role in neurodegeneration [128] . Even though changes in the levels of these metabolites have been detected in diagnosed patients, there is very low potential for 1 H-MRS to become an important tool in the diagnosis of neurodegenerative diseases without major development of labelling compounds or ways to dramatically increase sensitivity.
Imaging in cell therapy
The main modality of magnetic resonance that has been used for cell-based therapy in the brain is anatomical MRI (Fig. 4a,e) . The correct placement of the graft is very crucial for a successful outcome of cell-based therapy and here the MRI, with its excellent soft tissue contrast, has become a very valuable tool. Stereotactic guidance using MRI (Fig. 4d) is not without problems though. Owing to the way the three-dimensional image is built up in MRI using magnetic gradients, susceptibility artefacts or magnetic field wrapping can lead to distortions, displacing the structure of interest [129, 130] . Under well-controlled circumstances with careful shimming, studies have shown the MR image to be correct down to half a millimetre, so for most applications it is still very useful [131, 132] . In postsurgery imaging in combination with PET (Fig. 4c,g ), MRI can help estimate the success of the placement by looking at local changes in T2 relaxation in relationship with graft function as estimated by PET. Oedema caused by the surgical procedure, which may have a negative effect on graft survival, can also be detected. The use of functional MRI has given very few new insights into the neurodegeneration in the basal ganglia or the survival and function of neural transplants. One study suggested that there is a small but detectable increase in blood oxygenation level in areas with cell transplants in response to specific motor tasks [133] . Studies have also been conducted using MRS on human fetal transplants but owing to the low sensitivity of the technique and the non-specificity of the metabolites examined, the findings from this study can only be interpreted as proof of graft survival [134] .
Future prospects of PET and MRI
As mentioned earlier, the great versatility of PET as well as its exquisite sensitivity makes it indisputably the technique of the future for molecular imaging studies in ex- Fig. 4 . Schematic representation of the experimental paradigm used in brain imaging assessment of cell-based therapy in neurodegenerative diseases such as PD or HD. Pre-graft, patients receive pre-graft MRI (a) and a baseline PET scan (b) to assess the patient's brain in terms of anatomical and functional abnormality. These two data sets are merged to generate a composite image (c) in which the function (in the present case, glucose consumption rate) is superimposed on the anatomy. The pre-surgical MRI is also used to guide the stereotactic approach necessary to implant the cells into the targeted brain region (d). Post-surgical MRI and PET scans (e and f) are used to assess both the anatomical location of the grafted cells and their functional status. Again, merged MRI/PET images (g) are generated to better define the location of the grafted neurons into the host brain in relation to their biochemical status perimental animals and human beings. Almost every neurotransmitter, enzymatic or receptor system can be (or will be) imaged in the future using PET. Besides the already large panel of ligands selective for the dopamine system, radiochemists have now developed, and pharmacologists validated, hundreds of other radiotracers selective for various neurotransmitter systems such as the serotoninergic, noradrenergic, benzodiazepine, cholinergic, glutamatergic and glycinergic pathways [135] . In addition, selective inhibitors of various enzymes such as MAO-A and MAO-B have been radiolabelled with positron emitters. Even small inhibitory peptides or macromolecules like proteins, spiegelmers, aptamers or oligonucleotides can now be radiolabelled-the last-mentioned paving the way for in vivo quantification of gene expression [136] .
One of the major challenges of recent years has been to understand the molecular mechanisms underlying aberrant protein folding. Indeed, a key feature associated with nigrostriatal degeneration is the presence of intracellular protein aggregates, known as Lewy bodies, which can be seen in the surviving DA neurons of the substantia nigra. Although α-synuclein is recognised as the major component of Lewy inclusions, its exact role in the neurodegenerative process has still not been clearly elucidated [137, 138] . However, since the formation of aggregates has been shown to anticipate the occurrence of the symptoms, targeting characteristic components of these inclusions might be a clever way to assess the development of PD pathology. In the past few years, such an in vivo detection approach has been particularly successful in studies conducted in AD patients using radiolabelled compounds suitable for amyloid imaging using PET [139] [140] [141] . As an example, clinical data using the 11 C-labelled Pittsburg Compound-B ( 11 C-PIB) nicely showed an increase in PIB retention in several brain areas such as the frontal, parietal, temporal and occipital cortices, but also in the striatum, providing information on amyloid deposits in AD patients [140] . Similar tracers might also be particularly useful to detect neuronal abnormalities prior to the onset of the symptoms in PD, facilitating early diagnosis, but also for the followup of the evolution of disease. Ligands targeting specifically α-synuclein protein aggregates might hold promise in the development of such diagnostic approaches for PD, and complement the already existing markers, such as 2-β-carbomethoxy-3-β-(4-iodophenyl)tropane (β-CIT), dihydrotetrabenazine (DTBZ) or fluorodopa as an index of presynaptic dopaminergic activity or 11 C-raclopride as an index of post-synaptic D 2 receptor reactivity [142, 143] .
Beside these active developments of the PET technique on its own, the potential of PET may be further expanded by combining it with other in vivo techniques such as MRS. Especially with the advent of high-field MR spectrometers, which enable the direct quantification of up to 14-20 cerebral metabolites in the living patient brain, MRS gives access to various metabolites that are complementary to those accessible to PET, such as various neurotransmitters (glutamate, aspartate) and neuronal (NAA) and/or glial markers (alanine, glutamine). Perhaps more importantly, and unlike PET, MRS allows non-invasive measurements of metabolic fluxes in the human brain based on the detection of label incorporation (such as 13 C) into large pools of metabolites. Taking advantage of the unique property of MRS that allows specific identification of the molecule and the atomic position at which the isotopic label accumulates, pioneering studies have already demonstrated the feasibility of quantifying tricarboxylic acid cycling in vivo in neurons or astrocytes following infusion of 13 C-glucose or 13 C-acetate, as a substrate [144, 145] . Recent studies in a non-human primate model of HD have shown the interest of combining 18 F-FDG PET and 13 C-glucose MRS studies in the same animals to gain better insights into the metabolic consequences of mitochondrial impairment [146] . There is little doubt that in the near future, a similar combination of PET/MRS studies will be conducted in patients to elucidate the role of astroglia in supporting brain activity under diseased states. Similarly, MRS at a field strength of 7 T or higher may offer the possibility of identifying the degree of phenotypic maturation of fetal neuroblasts (characterised by their high lactate/NAA ratio) into fully differentiated, adult neurons (characterised by their high NAA/lactate ratio).
It is important to remember that 13 C has a natural abundance of 1.1%. This could be seen as an advantage because one can conduct 13 C spectroscopy looking at the natural abundance of 13 C in a tissue, but at the same time it is a disadvantage when using labelled compounds enriched for 13 C because of the high background in the brain. In addition, a second major limitation of 13 C as an NMR nucleus is the low magnetic resonance sensitivity, which is only about 1.6% of that of 1 H. A paramagnetic nucleus that has very low natural abundance in the brain but has a higher sensitivity than 13 C would be very valuable. A good candidate for this is fluorine ( 19 F). There is no naturally occurring 19 F in the brain and 100% of all fluorine is paramagnetic. Moreover, the magnetic resonance sensitivity of 19 F is 83% of that of 1 H, making it a good candidate for labelling. Along these lines, Higuchi and colleagues have created an amyloidophilic congo red type compound containing 19 F [147] . This compound crossed the bloodbrain barrier and showed low or no toxicity and good specificity for amyloid-β plaques. Using 19 F-MRI, Higuchi et al. were able to detect amyloid lesions and to visualise plaques occupying as little as 2.5% volume in some areas of the mouse brain. With the possible optimisation of this technique (using ligands with a higher number of fluorine atoms and higher kinetics over the blood-brain barrier) and the gain of the scaling factor to humans, this could prove to be a very cost-effective method for presymptomatic diagnosis of AD. Similar approaches could be used for imaging of other processes in the brain, e.g. visualisation of the dopamine system. Dingman and colleagues have recently published initial studies looking at the pharmacokinetics of a nine- 19 F-tagged variant of L-DOPA [148, 149] . Though still in its infancy, MRI or MRS measurements using 19 Flabelled compounds could prove to be a very valuable addition to the PET ligands available today.
Frequently asked questions on brain cell therapy and imaging
Are PET and MRI sensitive enough to visualise grafted cell function or anatomy in vivo?
PET, which is based on the use of radiolabelled-positronemitting-compounds is known to be the most sensitive method to detect externally trace amounts (around picomoles) of biotracer molecules. Published data clearly indicate that such sensitivity allows the function of the grafted cells to be visualised and quantified, in an absolute manner, in the living brain of a variety of experimental animals (rats, primates, pigs) as well as in patients. This is particularly true for radiotracers like false neurotransmitters or enzyme substrates that can accumulate with time in the grafted neurons. However, when the tracers used are targeting membranous proteins such as neuroreceptors or transporters, present in limited numbers on the grafted cells, PET may not be sensitive enough to detect the transplanted cells, especially if these cells are widely distributed within the host brain. With the development of high-resolution MRI methods, functional as well as anatomical imaging of individual grafted cells may become feasible-but this is still a largely unexplored field of research.
Will PET imaging still play a role when brain cell therapy is a routine clinical procedure?
Non-invasive brain imaging has been largely used in the past 10 years as a mean to monitor in vivo the loss of function occurring during the course of a neurodegenerative disorder and the progressive recovery following experimental therapeutics such as neuroprotective treatments or cell-based therapies. It is thus very likely that methods for monitoring of transplanted cells in vivo will continue to play a critical role in the future. Now that proof of principle for in vivo cell imaging in experimental and clinical trials has been obtained, efforts need to be made to develop new biomarkers with higher selectivity and sensitivity for the transplanted cells as compared with the host brain, to identify them unequivocally and to follow their fate in the host brain.
Could brain cell therapy be the cure for neurodegenerative diseases in the near future?
Several pre-clinical and clinical studies have shown that brain grafting may be therapeutically efficacious in a number of disease conditions such as PD, HD and ischaemia. Multi-centre phase I/II clinical trials are now under way that should establish the extent of therapeutic efficacy of cell-based therapies. Available data already demonstrate that clinical recovery following intracerebral grafting may be variable within and across patients. However, the elucidation of mechanisms which may be responsible for this within-and inter-individual variability may help define the optimal conditions for brain reconstruction.
What are the mechanisms by which cell-based therapies may improve brain function?
So far, two different strategies for brain repair following cell-based therapies have been tested, depending on the brain pathology considered. In the case of PD for which restoring normal dopamine levels within the diseased caudate-putamen complex (striatum) may be sufficient to induce a significant (though still not optimal) clinical recovery, ectopic striatal implantation of dopamine-producing cells has been shown to be effective. This is likely permitted by the fact that dopamine acts in the striatum as a neuromodulator of motor control neural circuits, rather than acting as a neurotransmitter within specific point-topoint neuronal circuits. In the case of HD, in which the neurodegeneration targets striatal GABAergic neurons that constitutively form part of the striato-pallido-thalamocortical circuits, the aim of neural grafting is to "recreate" the damaged circuit by replacing lost neurons in the circuit by new neurons. In both cases, intracerebral grafting has been shown to be equally effective-although the procedures still need to be improved to attain sufficient reproducibility in order to become a broadly clinically useful therapy.
